Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch

As the third to market, Merck & Co. Inc.'s recently launched Zepatier brought in a modest $50m in sales during the first quarter – but the drug has had an outsized impact on the hepatitis C field, with competitors Gilead Sciences Inc. and AbbVie Inc. both citing the new competition among the reasons for their declining HCV product sales during the first quarter.

While Zepatier – a combination of the protease inhibitor grazoprevir and NS5A inhibitor elbasvir, approved by FDA and launched in January – may not represent a great threat to Gilead's Harvoni (sofosbuvir/ledipasvir) and AbbVie's Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) on its own merits, the impact of a third and clearly cheaper regimen is weighing on both companies, especially with changes coming to the US HCV market. Access is being broadened to less-sick patients, which means more patients but shorter durations of therapy, as well as to VA and Medicaid patients, where steep discounts come into play.

Zepatier was approved by FDA on Jan. 28 and Merck immediately changed the game in terms of pricing. It set...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip